Breakthrough Device Designation for Quanterix’s Alzheimer’s Diagnostic
High-definition diagnostics company, Quanterix Corporation (Nasdaq: QTRX), has been granted Breakthrough Device designation by the FDA for its Simoa® phospho-Tau 217 (p-Tau 217) blood test as an aid in diagnostic evaluation of Alzheimer’s Disease (AD). p-Tau 217 has emerged as a top-performing biomarker for Alzheimer’s pathology.
“Early detection is crucial in shaping effective care strategies and improving patient outcomes,” said Masoud Toloue, CEO of Quanterix. “The breakthrough designation is an important step in our strategy to develop a global testing infrastructure for Alzheimer’s Disease. The FDA’s decision to grant Breakthrough Device Designation further validates the importance of accessible, non-invasive p-Tau 217 testing.”
Highlights
Traditional testing methods of positron emission tomography (PET) or lumbar puncture for cerebrospinal fluid (CSF) biomarkers are invasive and commonly inaccessible. Quanterix’s high-performing blood-based biomarker tests may provide an appropriate alternative for patient care.
Quanterix’s Simoa p-Tau 217 test is a semi-quantitative in vitro diagnostic immunoassay intended for the measurement of p-Tau 217 concentration in plasma using the Quanterix HD-X immunoassay system.
Proposed indications include use of the test results in patients presenting with cognitive impairment who are being evaluated for AD risk to aid in diagnostic evaluation. The test is not intended as a stand-alone diagnostic test and test results will be interpreted in conjunction with other diagnostic tools to establish a final clinical diagnosis.
The Breakthrough Device designation for the p-Tau 217 test underscores its potential to significantly impact Alzheimer’s disease (AD) diagnosis and treatment.
The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis of life-threatening diseases with an unmet medical need.
About Quanterix
From discovery to diagnostics, Quanterix’s ultra sensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,700 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.
